SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced the closing of its upsized initial public offering of an aggregate of 24,437,500 shares of its common stock at an initial public offering price of $18.00 per share, including the full exercise by the underwriters of their option to purchase 3,187,500 additional shares.

旧金山，2026年8月7日（环球电讯社）——Braveheart Bio, Inc.（纳斯达克股票代码：BRVE）是一家处于临床阶段的生物制药公司，致力于开发用于肥厚型心肌病（HCM）及其他严重心血管疾病的下一代疗法。该公司今日宣布，其扩大规模的首次公开发行（IPO）已正式完成，共计发行24,437,500股普通股，每股发行价为18.00美元，其中包括承销商全额行使购买3,187,500股额外股份的期权。

All shares of common stock were offered by Braveheart Bio. The shares began trading on the Nasdaq Global Market on August 6, 2026 under the ticker symbol “BRVE”..

Braveheart Bio 发售了所有普通股股份。该股票于 2026 年 8 月 6 日在纳斯达克全球市场开始交易，股票代码为“BRVE”。

The gross proceeds from the initial public offering, including full exercise of the underwriters’ option to purchase additional shares, before deducting underwriting discounts and commissions and offering expenses payable by Braveheart Bio, were $439.9 million.

在扣除承销折扣、佣金以及由Braveheart Bio支付的发行费用之前，包括完全行使承销商购买额外股份的选项，首次公开发行的总收益为4.399亿美元。

Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel and Cantor acted as joint book-running managers for the offering.

高盛集团、杰富瑞、TD Cowen、Stifel 和康托尔担任此次发行的联合账簿管理人。

Registration statements relating to the shares being sold in the initial public offering have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on August 5, 2026. The offering was made only by means of a prospectus, forming part of the effective registration statement relating to these shares.

与首次公开发行中出售的股份相关的注册声明已提交至美国证券交易委员会（SEC），并于2026年8月5日生效。本次发行仅通过构成该等股份有效注册声明一部分的招股说明书进行。

Copies of the final prospectus may be obtained from the SEC’s website at www.sec.gov and may also be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com..

最终招股说明书副本可从美国证券交易委员会（SEC）网站 www.sec.gov 获取，也可从以下机构获取：高盛有限责任公司（Goldman Sachs & Co. LLC），收件人：招股说明书部门，地址：200 West Street, New York, NY 10282，电话：(866) 471-2526，电子邮件：prospectus-ny@ny.email.gs.com；杰富瑞有限责任公司（Jefferies LLC），收件人：股票承销招股说明书部门，地址：520 Madison Avenue, New York, NY 10022，电话：(877) 821-7388，电子邮件：Prospectus_Department@Jefferies.com；道明证券（美国）有限责任公司（TD Securities (USA) LLC），转交 Broadridge Financial Solutions，地址：1155 Long Island Avenue, Edgewood, NY 11717，电子邮件：TDManualrequest@broadridge.com；Stifel, Nicolaus & Company, Incorporated，收件人：承销团，地址：One Montgomery Street, Suite 3700, San Francisco, CA 94104，电话：(415) 364-2720，电子邮件：syndprospectus@stifel.com；或 Cantor Fitzgerald & Co.，收件人：资本市场部，地址：110 East 59th Street, 6th Floor, New York, NY 10022，电子邮件：prospectus@cantor.com。

This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售要约或购买这些证券的要约邀请，也不得在任何州或司法管辖区进行这些证券的销售，如果在该州或司法管辖区，根据当地证券法，在注册或资格认证之前，此类要约、邀请或销售是非法的。

About Braveheart Bio

关于Braveheart Bio

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio’s lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).

Braveheart Bio 是一家处于临床阶段的生物制药公司，专注于为肥厚型心肌病（HCM）及其他严重心血管疾病患者开发疗法。Braveheart Bio 的核心候选产品 BHB-1893 是一种新一代口服小分子心脏肌球蛋白抑制剂（CMI），正在开发用于治疗梗阻性肥厚型心肌病（oHCM）和非梗阻性肥厚型心肌病（nHCM）。

Braveheart Bio’s goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, reversibility and reducing prescribing complexity..

Braveheart Bio 的目标是通过提高起效速度、增强梯度反应深度、保障收缩期安全性、实现可逆性以及降低处方复杂性，来改善这些患者的治疗选择。

Investor Relations Contact

投资者关系联系人

Alexander Sharif

亚历山大·沙里夫

New Street Investor Relations

新街投资者关系

Alexander@NewStreetIR.com

Alexander@NewStreetIR.com

Media Contact

媒体联系人

FGS Global

FGS Global

Braveheart-bio@fgsglobal.com

Braveheart-bio@fgsglobal.com